Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastrooesophageal junction cancer (KEYNOTE‑061): a randomised, open-label, controlled, phase 3 trial - Shitara, K; Ozguroglu, M; Bang, Y J (Lancet, 2018)
. doi:10.1016/S0140-6736(18)31257-1